An Innovative Testing Protocol to Study Foot and Ankle Kinetics during Early Stance Phase of Gait

The objective of this study was to improve upon existing testing platform limitations with respect to foot and ankle mechanics in the sagittal plane during dorsiflexion and plantar flexion. The intent was to develop a multi-loading protocol that simulated aspects of early stance phase of walking gait. This data were used to evaluate the influence an Achilles load has on the kinematic profile of the ankle complex. Also, resulting kinematic profile data can be used to evaluate ligament/tendon effects, ankle arthroplasty, and various surgical techniques. A pair of cadaveric human feet, from the same donor, 50 years of age were dissected and potted for testing. A pure moment protocol was developed to determine the path of least resistance or lowest energy state to rotate the tibia about the ankle complex. This protocol utilized a 4-degree of freedom robot coupled with a two 6-axis load cells. Positional data was used to calculate the instantaneous axis of rotation (IAR) of the ankle complex. The data was then normalized with respect to the widest distance across the tibia. Results from this work include a repeatability study of the robotic testing platform (RTP), validation of protocol, calculation of the IAR, and a study of the effect an Achilles load has on ankle kinematics. The repeatability study used a modified version of the protocol to reduce setup effects. A repeatability analysis was conducted comparing repeated test runs for dorsiflexion and plantar flexion (one way repeated measures ANOVA with a Bonferroni test) and found no significant difference between the data sets for (P\u3c0.05). The IAR results with and without a passive Achilles load were significantly different (P\u3e0.05), using same statistical approach. Future work is to actively drive the Achilles load and add a push-off condition were the rotation is about the distal end of the first and second metatarsals. Along with that, the upper limit of the vGRF is to be increased to simulate the later part of the stance phase of gait where the Achilles load is larger

Relationship between resistivity and specific heat in a canonical non-magnetic heavy fermion alloy system: UPt_5-xAu_x

UPt_(5-x)Au_x alloys form in a single crystal structure, cubic AuBe_5-type, over a wide range of concentrations from x = 0 to at least x = 2.5. All investigated alloys, with an exception for x = 2.5, were non-magnetic. Their electronic specific heat coefficient $\gamma$ varies from about 60 (x = 2) to about 700 mJ/mol K^2 (x = 1). The electrical resistivity for all alloys has a Fermi-liquid-like temperature variation, \rho = \rho_o + AT^2, in the limit of T -> 0 K. The coefficient A is strongly enhanced in the heavy-fermion regime in comparison with normal and transition metals. It changes from about 0.01 (x = 0) to over 2 micro-ohm cm/K^2 (x = 1). A/\gamma^2, which has been postulated to have a universal value for heavy-fermions, varies from about 10^-6 (x = 0, 0.5) to 10^-5 micro-ohm cm (mol K/mJ)^2 (x > 1.1), thus from a value typical of transition metals to that found for some other heavy-fermion metals. This ratio is unaffected, or only weakly affected, by chemical or crystallographic disorder. It correlates with the paramagnetic Curie-Weiss temperature of the high temperature magnetic susceptibility.Comment: 5 pages, 5 eps figures, RevTe

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.

High expression of ERBB2 has been reported in medulloblastoma and ependymoma; EGFR is amplified and over-expressed in brainstem glioma suggesting these proteins as potential therapeutic targets. We conducted a molecular biology (MB) and phase II study to estimate inhibition of tumor ERBB signaling and sustained responses by lapatinib in children with recurrent CNS malignancies. In the MB study, patients with recurrent medulloblastoma, ependymoma, and high-grade glioma (HGG) undergoing resection were stratified and randomized to pre-resection treatment with lapatinib 900 mg/m(2) dose bid for 7-14 days or no treatment. Western blot analysis of ERBB expression and pathway activity in fresh tumor obtained at surgery estimated ERBB receptor signaling inhibition in vivo. Drug concentration was simultaneously assessed in tumor and plasma. In the phase II study, patients, stratified by histology, received lapatinib continuously, to assess sustained response. Eight patients, on the MB trial (four medulloblastomas, four ependymomas), received a median of two courses (range 1-6+). No intratumoral target inhibition by lapatinib was noted in any patient. Tumor-to-plasma ratios of lapatinib were 10-20 %. In the 34 patients (14 MB, 10 HGG, 10 ependymoma) in the phase II study, lapatinib was well-tolerated at 900 mg/m(2) dose bid. The median number of courses in the phase II trial was two (range 1-12). Seven patients (three medulloblastoma, four ependymoma) remained on therapy for at least four courses range (4-26). Lapatinib was well-tolerated in children with recurrent or CNS malignancies, but did not inhibit target in tumor and had little single agent activity.Fil: Fouladi, Maryam. St. Jude Children’s Research Hospital; Estados UnidosFil: Stewart, Clinton F.. St. Jude Children’s Research Hospital; Estados UnidosFil: Blaney, Susan M.. Baylor College of Medicine. Texas Children’s Cancer Center; Estados UnidosFil: Onar Thomas, Arzu. St. Jude Children’s Research Hospital; Estados UnidosFil: Schaiquevich, Paula Susana. St. Jude Children’s Research Hospital; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Packer, Roger J.. Children’s National Medical Center; Estados UnidosFil: Goldman, Stewart. Anne and Robert H. Lurie Children’s Hospital of Chicago; Estados UnidosFil: Geyer, J. Rusell. Children’s Hospital and Regional Medical Center; Estados UnidosFil: Gajjar, Amar. St. Jude Children’s Research Hospital; Estados UnidosFil: Kun, Larry E.. St. Jude Children’s Research Hospital; Estados UnidosFil: Boyett, James M.. St. Jude Children’s Research Hospital; Estados UnidosFil: Gilbertson, Richard J.. St. Jude Children’s Research Hospital; Estados Unido